RAF Mutation clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.
San Francisco, California and other locations
Our lead scientists for RAF Mutation research studies include Katy Tsai, M.D..